CN1316279A - X-ray magnetic therapy machine for PDT therapy of cancer by combining radiatherapy with chemicotherapy and its medicine - Google Patents
X-ray magnetic therapy machine for PDT therapy of cancer by combining radiatherapy with chemicotherapy and its medicine Download PDFInfo
- Publication number
- CN1316279A CN1316279A CN 00117845 CN00117845A CN1316279A CN 1316279 A CN1316279 A CN 1316279A CN 00117845 CN00117845 CN 00117845 CN 00117845 A CN00117845 A CN 00117845A CN 1316279 A CN1316279 A CN 1316279A
- Authority
- CN
- China
- Prior art keywords
- radix
- prescription
- hmme
- chemicotherapy
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 41
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 238000002653 magnetic therapy Methods 0.000 title claims description 19
- 201000011510 cancer Diseases 0.000 title claims description 16
- 238000002560 therapeutic procedure Methods 0.000 title description 5
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 230000000694 effects Effects 0.000 claims abstract description 7
- 238000001959 radiotherapy Methods 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 105
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 56
- 238000002360 preparation method Methods 0.000 claims description 52
- 239000000243 solution Substances 0.000 claims description 49
- 210000000582 semen Anatomy 0.000 claims description 48
- 239000007788 liquid Substances 0.000 claims description 47
- 239000008187 granular material Substances 0.000 claims description 40
- 210000004369 blood Anatomy 0.000 claims description 36
- 239000008280 blood Substances 0.000 claims description 36
- 239000000843 powder Substances 0.000 claims description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 30
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 29
- 239000003094 microcapsule Substances 0.000 claims description 28
- 239000002775 capsule Substances 0.000 claims description 27
- 241000333181 Osmanthus Species 0.000 claims description 22
- 235000019082 Osmanthus Nutrition 0.000 claims description 22
- 229920002472 Starch Polymers 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 21
- 239000008107 starch Substances 0.000 claims description 21
- 235000019698 starch Nutrition 0.000 claims description 21
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- 239000006166 lysate Substances 0.000 claims description 17
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 16
- 102000016943 Muramidase Human genes 0.000 claims description 14
- 108010014251 Muramidase Proteins 0.000 claims description 14
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 14
- 239000004325 lysozyme Substances 0.000 claims description 14
- 229960000274 lysozyme Drugs 0.000 claims description 14
- 235000010335 lysozyme Nutrition 0.000 claims description 14
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 13
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 239000003921 oil Substances 0.000 claims description 12
- 238000010253 intravenous injection Methods 0.000 claims description 11
- 108010047620 Phytohemagglutinins Proteins 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- 238000002428 photodynamic therapy Methods 0.000 claims description 10
- 230000001885 phytohemagglutinin Effects 0.000 claims description 10
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 239000004365 Protease Substances 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 8
- 108090000526 Papain Proteins 0.000 claims description 8
- 102000004142 Trypsin Human genes 0.000 claims description 8
- 108090000631 Trypsin Proteins 0.000 claims description 8
- 229940055729 papain Drugs 0.000 claims description 8
- 235000019834 papain Nutrition 0.000 claims description 8
- 239000012588 trypsin Substances 0.000 claims description 8
- SWWQQSDRUYSMAR-UHFFFAOYSA-N 1-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol;hydrochloride Chemical group Cl.C1=CC(O)=CC=C1CC1C2=CC(O)=C(O)C=C2CCN1 SWWQQSDRUYSMAR-UHFFFAOYSA-N 0.000 claims description 7
- 206010006895 Cachexia Diseases 0.000 claims description 7
- 102000008857 Ferritin Human genes 0.000 claims description 7
- 108050000784 Ferritin Proteins 0.000 claims description 7
- 238000008416 Ferritin Methods 0.000 claims description 7
- 239000010231 banlangen Substances 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 229920001971 elastomer Polymers 0.000 claims description 7
- 150000004676 glycans Chemical class 0.000 claims description 7
- 210000000496 pancreas Anatomy 0.000 claims description 7
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- 230000010349 pulsation Effects 0.000 claims description 7
- 241000717739 Boswellia sacra Species 0.000 claims description 6
- 206010058019 Cancer Pain Diseases 0.000 claims description 6
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 6
- 241000628997 Flos Species 0.000 claims description 6
- 239000004863 Frankincense Substances 0.000 claims description 6
- 241000238631 Hexapoda Species 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 230000001066 destructive effect Effects 0.000 claims description 6
- 239000000890 drug combination Substances 0.000 claims description 6
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 6
- 239000011505 plaster Substances 0.000 claims description 6
- 201000000849 skin cancer Diseases 0.000 claims description 6
- 201000008261 skin carcinoma Diseases 0.000 claims description 6
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 5
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims description 5
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims description 5
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims description 5
- 229940011037 anethole Drugs 0.000 claims description 5
- 230000004927 fusion Effects 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 229940100243 oleanolic acid Drugs 0.000 claims description 5
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 claims description 5
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 5
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 4
- 239000009636 Huang Qi Substances 0.000 claims description 4
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims description 4
- 241001250596 Pleione Species 0.000 claims description 4
- 229940089161 ginsenoside Drugs 0.000 claims description 4
- 229930182494 ginsenoside Natural products 0.000 claims description 4
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 4
- 239000001095 magnesium carbonate Substances 0.000 claims description 4
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 4
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 4
- 239000003504 photosensitizing agent Substances 0.000 claims description 4
- 229910052957 realgar Inorganic materials 0.000 claims description 4
- 239000009286 sanguis draxonis Substances 0.000 claims description 4
- 241000269417 Bufo Species 0.000 claims description 3
- 235000018958 Gardenia augusta Nutrition 0.000 claims description 3
- 240000008669 Hedera helix Species 0.000 claims description 3
- 208000032843 Hemorrhage Diseases 0.000 claims description 3
- 240000003183 Manihot esculenta Species 0.000 claims description 3
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 3
- 229940031955 anhydrous lanolin Drugs 0.000 claims description 3
- 239000007766 cera flava Substances 0.000 claims description 3
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 235000008434 ginseng Nutrition 0.000 claims description 3
- 239000000391 magnesium silicate Substances 0.000 claims description 3
- 229940099273 magnesium trisilicate Drugs 0.000 claims description 3
- 229910000386 magnesium trisilicate Inorganic materials 0.000 claims description 3
- 235000019793 magnesium trisilicate Nutrition 0.000 claims description 3
- 230000037257 muscle growth Effects 0.000 claims description 3
- XRRONFCBYFZWTM-UHFFFAOYSA-N octadecanoic acid;sodium Chemical compound [Na].CCCCCCCCCCCCCCCCCC(O)=O XRRONFCBYFZWTM-UHFFFAOYSA-N 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 229910052710 silicon Inorganic materials 0.000 claims description 3
- 239000010703 silicon Substances 0.000 claims description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000003871 white petrolatum Substances 0.000 claims description 3
- 244000188405 Knoxia valerianoides Species 0.000 claims description 2
- 241001057584 Myrrha Species 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 238000005520 cutting process Methods 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims description 2
- 230000037213 diet Effects 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000007902 hard capsule Substances 0.000 claims 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims 1
- 244000235603 Acacia catechu Species 0.000 claims 1
- 235000006226 Areca catechu Nutrition 0.000 claims 1
- 244000097863 Grifola umbellata Species 0.000 claims 1
- 235000002897 Grifola umbellata Nutrition 0.000 claims 1
- 241000521257 Hydrops Species 0.000 claims 1
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 235000004837 Polyporus umbellatus Nutrition 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 206010000269 abscess Diseases 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000007123 defense Effects 0.000 claims 1
- 238000009513 drug distribution Methods 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 238000003756 stirring Methods 0.000 description 54
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 34
- 229960004756 ethanol Drugs 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
- 238000001556 precipitation Methods 0.000 description 27
- 238000000034 method Methods 0.000 description 26
- 238000001035 drying Methods 0.000 description 21
- 239000000706 filtrate Substances 0.000 description 20
- 238000002425 crystallisation Methods 0.000 description 18
- 230000008025 crystallization Effects 0.000 description 18
- 239000000284 extract Substances 0.000 description 18
- 102000001554 Hemoglobins Human genes 0.000 description 14
- 108010054147 Hemoglobins Proteins 0.000 description 14
- 238000001914 filtration Methods 0.000 description 14
- 239000007864 aqueous solution Substances 0.000 description 13
- -1 filter Substances 0.000 description 13
- 238000000605 extraction Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 239000000796 flavoring agent Substances 0.000 description 11
- 235000019634 flavors Nutrition 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 9
- 239000001263 FEMA 3042 Substances 0.000 description 9
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 238000010298 pulverizing process Methods 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 229920002258 tannic acid Polymers 0.000 description 9
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 9
- 229940033123 tannic acid Drugs 0.000 description 9
- 235000015523 tannic acid Nutrition 0.000 description 9
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 8
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 8
- 235000011130 ammonium sulphate Nutrition 0.000 description 8
- 238000004821 distillation Methods 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 102000002322 Egg Proteins Human genes 0.000 description 7
- 108010000912 Egg Proteins Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 238000013019 agitation Methods 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 6
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 description 6
- 229940095758 cantharidin Drugs 0.000 description 6
- 229930008397 cantharidin Natural products 0.000 description 6
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000000385 dialysis solution Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 239000003978 infusion fluid Substances 0.000 description 6
- 210000004681 ovum Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000000341 volatile oil Substances 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 239000002156 adsorbate Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000011218 segmentation Effects 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000005995 Aluminium silicate Substances 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- JPIDYDMHPUUAHX-WORMITQPSA-N BrC(C)C=1C(=C2NC=1C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N=1)=C2)[2H] Chemical compound BrC(C)C=1C(=C2NC=1C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N=1)=C2)[2H] JPIDYDMHPUUAHX-WORMITQPSA-N 0.000 description 3
- 101001066878 Homo sapiens Polyribonucleotide nucleotidyltransferase 1, mitochondrial Proteins 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 241000283898 Ovis Species 0.000 description 3
- 102000002681 Polyribonucleotide nucleotidyltransferase Human genes 0.000 description 3
- 102000007501 Thymosin Human genes 0.000 description 3
- 108010046075 Thymosin Proteins 0.000 description 3
- 102000011759 adducin Human genes 0.000 description 3
- 108010076723 adducin Proteins 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- BIGPRXCJEDHCLP-UHFFFAOYSA-N ammonium bisulfate Chemical compound [NH4+].OS([O-])(=O)=O BIGPRXCJEDHCLP-UHFFFAOYSA-N 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 238000010612 desalination reaction Methods 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- UCMLAGLRLOPBAX-PRRDBKRISA-N (3as,4r,7s,7ar)-3a,7a-dimethyl-2-[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]-4,5,6,7-tetrahydro-octahydro-1h-4,7-epoxyisoindole-1,3-dione Chemical compound C1=C(OC(F)(F)F)C=C2SC(N3C(=O)[C@]4(C)[C@H]5CC[C@H](O5)[C@@]4(C3=O)C)=NC2=C1 UCMLAGLRLOPBAX-PRRDBKRISA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical class [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- NWGKJDSIEKMTRX-MDZDMXLPSA-N Sorbitan oleate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(O)C1OCC(O)C1O NWGKJDSIEKMTRX-MDZDMXLPSA-N 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 2
- 238000003811 acetone extraction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000035614 depigmentation Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- PJXISJQVUVHSOJ-UHFFFAOYSA-N indium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[In+3].[In+3] PJXISJQVUVHSOJ-UHFFFAOYSA-N 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000013307 optical fiber Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000011265 semifinished product Substances 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- VAJVGAQAYOAJQI-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-3,8,13,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C(C=C2C(C)=CC(N2)=CC=2C(=C(CCC(O)=O)C(=C3)N=2)C)=CC(C)=C1C=C1C(C)=C(CCC(O)=O)C3=N1 VAJVGAQAYOAJQI-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical group CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
- 241000131283 Cantharis Species 0.000 description 1
- 241001122126 Carex secta Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 241000222640 Polyporus Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000545442 Radix Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 125000000218 acetic acid group Chemical class C(C)(=O)* 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000009188 angelicae sinensis extract Substances 0.000 description 1
- 230000001727 anti-capsular Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 235000019987 cider Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 229960003569 hematoporphyrin Drugs 0.000 description 1
- 238000007731 hot pressing Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical class [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000001771 vacuum deposition Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
An X-ray magnetic therapeutic machine for the PDT of cancers features that it can output the mixed electromagneitc wave beams of X ray and laser to improve the curative effect of chemicotherapy and radiotherapy to shrink the size of tumor to less than 3 sq.cm, which can fully play the role of PDT (up to 90% or higher). A series of medicines to be used in conjuction with said machine is also disclosed.
Description
The present invention relates to a kind of treatment greater than 3cm
2Above tumor merges chemicotherapy and dwindles the tumor body to carry out optical dynamic therapy (PDT) used X-ray magnetic therapy machine and medicine thereof.
At present, the routine treatment of treatment cancer mainly is operation, chemicotherapy.Operation can only be applicable to the case that meets the indication of performing the operation, and has limitation.Chemicotherapy only can play most of cancer patient and dwindle lump, prolongs the effect of life, and the case that can reach recent healing seldom.And chemicotherapy also exists toxic and side effects big, drawbacks such as prognostic difference.Both made the tumor photodynamic therapy (PDT) of in the treatment and prevention of tumour science, having shown up prominently, also exist photosensitizer draw back at tumor tissues and normal surrounding tissue Chinese medicine concentration difference end greatly different distance and laser irradiation less than the position, defective and deficiency that can't the deactivation cancerous cell.
The purpose of this invention is to provide a kind ofly, can play, improve, the potentiation chemicotherapy supports that chemicotherapy dwindles the tumor body to 3cm
2Below, so that carry out photodynamic tumor treatment (PDT), a series of chemicotherapy drug combinations that make the cancer patient can reach the X-ray magnetic therapy machine of recent healing (CR) and match.
X-ray magnetic therapy machine of the present invention is mainly by (1) X-ray apparatus (180KV, 10mA, 0.5mmCU) six parts such as (2) ruby laser apparatus (available cuprous bromide copper laser replace) (3) charged particle accelerator device (4) pulsation Magnetotherapeutic apparatus (5) thermostat (6) specialty optical fiber are formed.
For the tumor body is contracted to below the 3cm2, make tumor photodynamic therapy can bring into play its curative effect, just must can be achieved in conjunction with the X-ray magnetic therapy machine in order to following chemicotherapy drug combination.Because tumor photodynamic therapy (PDT) is only applicable to esophagus, stomach, lung, liver, mammary gland, nasopharynx, rectum colon, bladder, uterus, these ten kinds of cancers of skin portion are so the anti-compound recipe complex capsule in osmanthus has designed the concrete prescription at these ten kinds of cancers.
One, the anti-compound recipe complex capsule in osmanthus
Basis side is Ramulus Cinnamomi, Poria, Cortex Moutan, Semen Persicae, each 9g of Radix Paeoniae 1..(directly making granule)
2. Herba Agrimoniae 100g, Herba Solani Lyrati 30g, Herba Solani Nigri 2 5g, Semen Arecae 15g, Rhizoma Pinelliae Preparata 10g, Radix Glycyrrhizae 5g.(system enteric-coated microcapsule granule)
1. esophageal carcinoma prescription (anti-relapse due to improper diet side, osmanthus complex capsule) Herba Agrimoniae 100g, Herba Solani Lyrati 30g, Herba Solani Nigri 25g, Semen Arecae 15g, Rhizoma Pinelliae Preparata 10g, Radix Glycyrrhizae 5g, Semen Impatientis 30g, Ramulus Cinnamomi, Poria, Cortex Moutan, Semen Persicae, each 9g of Radix Paeoniae.
2. gastric cancer prescription (osmanthus anti-stomach compound recipe complex capsule) Herba Agrimoniae 100g, Herba Solani Lyrati 30g, Herba Solani Nigri 25g, Semen Arecae 15g, Rhizoma Pinelliae Preparata 10g, Radix Glycyrrhizae 5g, Radix Codonopsis 15g, Rhizoma Atractylodis Macrocephalae 10g, Poria 15g, Ramulus Cinnamomi, Cortex Moutan, Semen Persicae, each 9g of Radix Paeoniae.
3. pulmonary carcinoma prescription (osmanthus anti-lung compound recipe complex capsule) Herba Agrimoniae 100g, Herba Solani Lyrati 30g, Herba Solani Nigri 25g, Semen Arecae 15g, Rhizoma Pinelliae Preparata 10g, Radix Glycyrrhizae 5g, Rhizoma Imperatae 30g, Radix Astragali 25g, Fructus Trichosanthis 20g, Ramulus Cinnamomi, Poria, Cortex Moutan, Semen Persicae, each 9g of Radix Paeoniae.
4. hepatocarcinoma prescription (osmanthus anti-liver compound recipe complex capsule) Herba Agrimoniae 100g, Herba Solani Lyrati 30g, Herba Solani Nigri 25g, Semen Arecae 15g, Rhizoma Pinelliae Preparata 10g, Radix Glycyrrhizae 5g, Rhizoma Curcumae, each 15g of rhizoma sparganic, Ramulus Cinnamomi, Poria, Cortex Moutan, Semen Persicae, each 9g of Radix Paeoniae.
5. breast carcinoma prescription (osmanthus resists newborn compound recipe complex capsule) Herba Agrimoniae 100g, Herba Solani Lyrati 30g, Herba Solani Nigri 25g, Semen Arecae 15g, Rhizoma Pinelliae Preparata 10g, Radix Glycyrrhizae 5g, Herba Taraxaci, each 30g of Herba Violae, Ramulus Cinnamomi, Poria, Cortex Moutan, Semen Persicae, each 9g of Radix Paeoniae.
6. nasopharyngeal carcinoma prescription (osmanthus anti-nose compound recipe complex capsule) Herba Agrimoniae 100g, Herba Solani Lyrati 30g, Herba Solani Nigri 25g, Semen Arecae 15g, Rhizoma Pinelliae Preparata 10g, Radix Glycyrrhizae 5g, Flos Lonicerae 30g, Herba Asari 10g, 5 pieces in Fructus Jujubae, Ramulus Cinnamomi, Poria, Cortex Moutan, Semen Persicae, each 9g of Radix Paeoniae.
7. rectum, colon cancer prescription (osmanthus anti-intestinal compound recipe complex capsule) Herba Agrimoniae 100g, Herba Solani Lyrati 30g, Herba Solani Nigri 25g, Semen Arecae 15g, Rhizoma Pinelliae Preparata 10g, Radix Glycyrrhizae 5g, Spina Gleditsiae 25g, Radix Sanguisorbae 30g, JIUHUANGLING 10g, Ramulus Cinnamomi, Poria, Cortex Moutan, Semen Persicae, each 9g of Radix Paeoniae.
8. bladder cancer prescription (osmanthus anti-wing compound recipe complex capsule) Herba Agrimoniae 100g, Herba Solani Lyrati 30g, Herba Solani Nigri 25g, Semen Arecae 15g, Rhizoma Pinelliae Preparata 10g, Radix Glycyrrhizae 5g, Folium Pyrrosiae 30g, Herba Hedyotidis Diffusae 15g, Rhizoma Imperatae 30g, Ramulus Cinnamomi, Poria, Cortex Moutan, Semen Persicae, each 9g of Radix Paeoniae.
9. uterus carcinoma prescription (anti-palace, osmanthus compound recipe complex capsule) Herba Agrimoniae 100g, Herba Solani Lyrati 30g, Herba Solani Nigri 25g, Semen Arecae 15g, Rhizoma Pinelliae Preparata 10g, Radix Glycyrrhizae 5g, Herba Solani Lyrati 30g, Cacumen Platycladi 30g, Ramulus Cinnamomi, Poria, Cortex Moutan, Semen Persicae, each 9g of Radix Paeoniae.
10. skin carcinoma prescription (osmanthus anti-skin compound recipe complex capsule) Herba Agrimoniae 100g, Herba Solani Lyrati 30g, Herba Solani Nigri 25g, Semen Arecae 15g, Rhizoma Pinelliae Preparata 10g, Radix Glycyrrhizae 5g, Cortex Dictamni 30g, Rhizoma Smilacis Glabrae, Radix Sophorae Tonkinensis, each 15g of Flos Lonicerae, Ramulus Cinnamomi, Poria, Cortex Moutan, Semen Persicae, each 9g of Radix Paeoniae.
Because the anti-capsular preparation methoies in above ten kinds of osmanthus are identical, thus be example with the pulmonary carcinoma prescription, the preparation method of the anti-compound recipe complex capsule in narration osmanthus.
Prescription: Ramulus Cinnamomi, Poria, Cortex Moutan, Semen Persicae, each 9g of Radix Paeoniae (directly making granule).
Method for making: the above five tastes, Ramulus Cinnamomi, Cortex Moutan, Semen Persicae extract volatile oil, and the aqueous solution after distillation device is in addition collected, medicinal residues and Poria, Radix Paeoniae two flavors decoct with water secondary, each 2h, collecting decoction, filter, the aqueous solution after filtrate and the distillation merges, and is concentrated into 1/2 of original volume, add 3 times of amount 95% ethanol, the limit edged stirs, and 24h is placed in cold preservation, filter, disgorging reclaims ethanol, put and be chilled to room temperature, filter, cleaner liquid is condensed into thick paste, adds starch and ethanol and makes granule in right amount, dry, granulate is crossed 40 mesh sieves, and granule sprays volatile oil such as adding Ramulus Cinnamomi again, mixing, promptly.
Add the flavor prescription: Herba Agrimoniae, 100g, Herba Solani Lyrati 30g, Herba Solani Nigri 25g, Semen Arecae 15g, Rhizoma Pinelliae Preparata 10g, Radix Glycyrrhizae 5g, Rhizoma Imperatae 30g, Radix Astragali 25g, Fructus Trichosanthis 20g.(system enteric-coated microcapsule granule)
Method for making:
(1) extract above nine flavors, Herba Agrimoniae is fried in shallow oil in addition, and all the other medicines decoct with water 2 times together, each 2h.Merge all decocting liquids, be concentrated to 1/2 of original volume, add 3 times of amount 95% ethanol, the limit edged stirs, and 24h is placed in cold preservation, filters, and disgorging reclaims ethanol, puts and is chilled to room temperature, filters, and filtrate is concentrated into fluid extract.
(2) parcel is transferred to above-mentioned fluid extract in the gelatin solution of 3%-5%, fully stir, it is an amount of under agitation to add water then, put in the water-bath and to keep 50 ℃, continue to stir, add 10% acetum, regulate pH value 3.5~3.6, at test under microscope, must proof produce cohesion, and see complete spheroidal microcapsule.
(3) being solidificated in above-mentioned microcapsule forms in the liquid, the formalin of adding 37%, continue to stir and further cooling, and it is an amount of to add cold distilled water, adds the frozen water cooling at reactor, makes microcapsule form liquid and reduces to 3~5 ℃, continuous stirring, behind about 1h, reuse 20% sodium hydroxide solution is adjusted pH value 8~9, and the network structure hole of gel is dwindled.
(4) after dispersion continues to stir 0.5h, add 10% living starch slurry suspension starch is fully scattered, formation one sealing coat is kept below 10 ℃ restir 1~2h between microcapsule.
(5) dry with the above-mentioned microcapsule of making, suction strainer separates, and washing eliminates moisture as far as possible, and with 40 mesh sieve system granules, the starch that progressively adds dry (60 ℃ of dry 3h) in the system granule is an amount of, makes loose particles, after one time 40 mesh sieve, and 60 ℃ of dry 2h.
(6) enteric coated Cellulose Acetate Phthalate (CAP) is made into 6% anhydrous propanone solution, get its 6 parts with 20% Lac, 1 part of mixing of ethanol solution, evenly, promptly make enteric coating solution, use air suspension coating machine that above-mentioned microcapsule granule is enteric coated then, promptly.
Osmanthus anti-lung compound recipe complex capsule
Method for making: will write out a prescription the 1. granule and the 2. enteric-coated microcapsule granule mixing of writing out a prescription, in the empty hard softgel shell of the certain specification of packing into, promptly.
Skin carcinoma ointment for promoting muscle growth prescription, method for making
Write out a prescription 1.: the Radix Angelicae Dahuricae, Radix Arnebiae (Radix Lithospermi), Radix Angelicae Sinensis, Rhizoma Arisaematis, Rhizoma Pinelliae, Semen Hyoscyami, Olibanum, Myrrha, Cortex Phellodendri, Radix Scutellariae, Rhizoma Coptidis, Indigo Naturalis, Radix Aconiti, Radix Aconiti Kusnezoffii, Radix Glycyrrhizae, a little tea, Semen phaseoli radiati powder, each equivalent of Calamina.
Method for making: above 18 flavors of pharmacy oil, except that Semen phaseoli radiati powder was standby, 17 flavor coarse pulverizations such as all the other Radixs Angelicae Dahuricae, Radix Arnebiae (Radix Lithospermi) were put in purified Oleum Gossypii semen or the Oleum Sesami and were soaked 24 hours, endured to medicine is withered with slow fire and floated for degree, filtered clean medicinal residues, promptly got medicine oil.Use pharmaceutical grade activated carbon decolorizing element then.
Write out a prescription 2.: above-mentioned medicine oil 192g, Semen phaseoli radiati powder 57.6g, Borneolum Syntheticum 6g, Cera Chinensis 7.2g, anhydrous lanolin 2.4g, Cera Flava 7.2g, jasmin essence 0.18g, white vaseline 12g.
Method for making: above eight flavors, Semen phaseoli radiati powder system micropowder is crossed 120 mesh sieves, the Borneolum Syntheticum porphyrize, above-mentioned depigmentation agents oil is heated to more than 100 ℃, and fine straining is put in the container, and insulation is placed, Cera Flava, Cera Chinensis are heated to 100 ℃, add white vaseline and anhydrous lanolin, after the fusing, filter, make substrate, get substrate 30g heating and melting, add above-mentioned depigmentation agents oil and stir evenly, put and be chilled to 70 ℃, add above-mentioned Semen phaseoli radiati powder, stirring and evenly mixing is cooled to 50 ℃, add Borneolum Syntheticum and jasmin essence, stir evenly, promptly.
Esophageal carcinoma blocks alleviates containing sugar-tablet
Prescription: Pseudobulbus Cremastrae Seu Pleiones, Galla Chinensis 60g, Semen Euphorbiae 30g, Moschus, each 9g of Realgar, Sal Ammoniacus, each 7g of Calculus Bovis, Knoxia valerianoides 45g, an amount of Oleum sesami, syrup.
Preparation method: Sal Ammoniacus is put into porcelain pulverization (keeping away metal), adds water boil, filters extracting juice, with vinegar (500g juice adds 500g vinegar), fries in shallow oil again, until boiling dry, gets the lark crystalline powder.
More than eight flavors, the Sal Ammoniacus crystallization is ground, Calculus Bovis, Realgar water fly; Moschus powder is broken into impalpable powder (above-mentioned medicated powder is crossed 100 mesh sieves), and four flavors such as all the other Pseudobulbus Cremastrae Seu Pleioness decoct with water 2 times, each 2h; merge and boil liquid, filter, filtrate is condensed into thick paste; it is an amount of to add Calculus Bovis, Sal Ammoniacus, Realgar, Moschus powder and concentration and be 50%~70% syrup; the system granule, drying, mixing; spray adds that correctives---slow fire burns to 8 sophisticated Oleum sesami, is pressed into and sucks sugar-tablet then.
Three plerosis side's complex capsules
Write out a prescription 1.: Radix Ginseng, each 8g of Cortex Cinnamomi, Rhizoma Chuanxiong 5g, Radix Rehmanniae Preparata 15g, Poria 8g, Rhizoma Atractylodis Macrocephalae preparata 10g, Radix Glycyrrhizae Preparata 5g, Radix Astragali 15g, Radix Angelicae Sinensis 10g, Radix Paeoniae Alba 8g.(directly making granule)
Method for making: above ten flavors, Cortex Cinnamomi, Rhizoma Chuanxiong, Radix Angelicae Sinensis extract volatile oil, and the aqueous solution after distillation device is in addition collected, medicinal residues and all the other seven flavors decoct with water secondary, each 2h, collecting decoction, filter, the aqueous solution after filtrate and the distillation merges, and is concentrated into 1/2 of original volume, add 3 times of amount 95% ethanol, the limit edged stirs, and 24h is placed in cold preservation, remove by filter precipitate, reclaim ethanol, add alcohol equally and handle, repeat 1 time, cleaner liquid is condensed into thick paste, add starch and ethanol and make granule, drying, granulate in right amount, cross 40 mesh sieves, granule sprays volatile oil such as adding Cortex Cinnamomi again, mixing, promptly.
Write out a prescription 2.: maljoe, Seem Lablab Album phytohemagglutinin (PHA) 50mg, saikoside D and each 40mg of Radix Bupleuri polysaccharide, polyporusum bellatus 40mg.
1. the extracting method of maljoe, Seem Lablab Album phytohemagglutinin (PHA)
Semen Canavaliae peeling, the porphyrize powder, with ethanol and ether defatting, drying, porphyrize powder again after adding 5 times of amount 0.2% sodium hydroxide and stirring, adds dilute hydrochloric acid and transfers PH to 6.8, and refrigerator (4 ℃) standing over night is centrifugal, the reject precipitation, the leaching supernatant is with the G200 gel chromatography.The upper column quantity stock solution of supernatant is 0.5%~1% (V/V) flow velocity 5ml/30 minute of gel column volume, at room temperature carries out, and collects with the segmentation automatic collector, and every pipe 5ml detects with the hemagglutination method, and its PHA is among 20~40 pipes.Merge the solution of 20~40 pipes, drain, promptly get pure product PHA with frozen vacuum dryer.The conjugate of this strain protein and polysaccharide, i.e. glycoprotein.
2. the extracting method of polyporusum bellatus
1. extract: go earth to make fragment the 50kg Polyporus, add the hot pressing of 5 times of amount distilled water and extract 3 times for 115.5 ℃, each time was respectively 1.5,1,0.5 hours, merged 3 times filtrate, removed insoluble impurities, got extracting solution.
2. concentrate, precipitate: said extracted liquid is evaporated to 5L, under agitation adds ethanol, makes pure content reach 80%, leaves standstill 12 hours, filters the collecting precipitation cold drying.Again dry thing is dissolved in the 3L distilled water, after the heated and boiled, filtering insoluble matter while hot, filtrate under agitation adds ethanol and reaches 80% concentration, leaves standstill 24 hours, filter, collecting precipitation, with washing with alcohol 3 times, cold drying, semifinished product, yield about 0.65%.
3. foreigh protein removing, decolouring, precipitation:
Crude product is dissolved in the 3L distilled water, accurately measure 30ml, under agitation drip 1% tannic acid (medicinal specification) solution, the limit edged heats up, and boils the centrifugal precipitation that discards in back, add 1 haze-free ending of tannic acid liquid to getting supernatant, converse crude product liquid and need add the amount of tannic acid liquid,, under agitation add 1% tannic acid liquid lentamente earlier with crude product liquid heated and boiled, after question response is complete, continued to boil 15 minutes, the active carbon of adding 2% stirred 10 minutes, filtered with buchner funnel, filtrate adds concentration of alcohol and reaches 70%, after leaving standstill 24 hours, filter, precipitate with 70% ethanol cyclic washing, till not having tannic acid to washing liquid, the wet product of precipitate.
4. absorption, eluting, precipitation, drying:
The product of wetting are dissolved in 2L, in 20% the hot ethanol, by placing the 2kg neutral alumina layer of buchner funnel, decompression is slightly slowly flowed out, and continues the hot distilled water eluting of adding 60%, collect the effluent concentrating under reduced pressure and become 2.5L, add concentration and reach 70% ethanol, place and promptly separate out white flocculent deposit, filter, collect, precipitation, low temperature or lyophilization promptly get the pure product of polyporusum bellatus.
3. the extraction therapy of saikoside D and Radix Bupleuri polysaccharide
The Radix Bupleuri coarse pulverization with methanol room temperature lixiviate 3 days, is reclaimed methanol, and residue is dissolved in weak ammonia, chloroform extraction, and the residue behind the recovery chloroform is dissolved in 90% methanol, with defat with petroleum ether, reclaims methanol and gets Radix Bupleuri soap D.
Radix Bupleuri medicinal residues after the methanol lixiviate extract the Radix Bupleuri polysaccharide according to the extraction step of above-mentioned polyporusum bellatus.
The 2. particulate preparation method of enteric-coated microcapsule of writing out a prescription
Method for making:
(1) dissolving is with 50mg, and maljoe phytohemagglutinin (PHA) and saikoside D and each 40mg of Radix Bupleuri polysaccharide and polyporusum bellatus 40mg are dissolved in an amount of 0.9%Nacl solution, stir evenly, and make concentrated solution.
(2) parcel moves to above-mentioned lysate in 3%~5% the gelatin solution, fully stir, it is an amount of under agitation to add water then, put in the water-bath and to keep 50 ℃, continue to stir, add 10% acetum, regulate PH3.5~3.6, at test under microscope, must proof produce agglutination, and see complete spheroidal microcapsule.
(3) being solidificated in above-mentioned microcapsule forms in the liquid, the formalin of adding 37%, continue to stir and further cooling, and it is an amount of to add cold distilled water, adds the frozen water cooling at reactor, makes microcapsule form liquid and reduces to 3~5 ℃, continuous stirring, behind about 1h, reuse 20% sodium hydroxide solution is adjusted PH8~9, and the network structure hole of gel is dwindled.
(4) after dispersion continues to stir 0.5h, add 10% and give birth to the starch slurry suspension, starch is fully scattered, formation one sealing coat is kept below 10 ℃ restir 1~2h between microcapsule.
(5) dry with the above-mentioned microcapsule of making, suction strainer separates, washing, eliminates moisture content as far as possible, and with 40 mesh sieve system granules, the starch that progressively adds dry (60 ℃ of dry 3h) in the granule is an amount of, makes loose particles, after one time 40 mesh sieve, and 60 ℃ of dry 2h.
(6) enteric coated Cellulose Acetate Phthalate (CAP) is made into 6% anhydrous propanone solution, get its 6 parts with 20% Lac, 1 part of mixing of ethanol solution, evenly, promptly make enteric coating solution, use air suspension coating machine that above-mentioned microcapsule granule is enteric coated then, promptly.
The preparation of three plerosis side's complex capsules
Method for making: will write out a prescription the 1. granule and the 2. enteric-coated microcapsule granule mixing of writing out a prescription, in the empty hard softgel shell of the certain specification of packing into, promptly.
XIAOLIU PIAN
Prescription 1: Rhizoma Bolbostematis, each 20g of Pseudobulbus Cremastrae Seu Pleiones, Semen Euphorbiae 15g, Fructus Aurantii 30g, Resina Toxicodendri (stir-fry) 6g, Oletum Trogopterori 15g, Radix Curcumae 18g, Alumen 18g, Herba Agrimoniae 18g, Sal Nitri 18g, Semen Strychni (processed) 12g.
The write out a prescription method for making of 1 extract
More than ten simply, Alumen, Sal Nitri levigation, Resina Toxicodendri, Oletum Trogopterori are pulverized.Seven flavors such as all the other Rhizoma Bolbostematiss decoct with water secondary, every 2h, and merging filtrate is condensed into thick paste.Add Resina Toxicodendri, Oletum Trogopterori fine powder and 2 the appropriate amount of starch of writing out a prescription, fully suction, and then Alumen, Sal Nitri powder added mixing, make granule, drying.
Prescription 2: 1 extract 1750g, starch 250g, magnesium stearate 100g write out a prescription.
The method for making of prescription 2
Take by weighing above-mentioned prescription 1 granule 1750g, add remaining starch, be ground into 14 order granules, add the magnesium stearate mixing, tabletting is used the Indigo Naturalis coating, every heavy 0.2g.
Town's cancer pain rubber plaster
The preparation of Chinese medicine condensed cream
Prescription: Bufo siccus (doing all), Semen Strychni 20g, a Flos Carthami 30g, Rhizoma Curcumae Longae, Cinnabaris, each 15g of Olibanum, Moschus 2g, Mentholum 30g, Herba Aristolochiae 30g, Radix Ilicis Pubescentis, each 15g of Sanguis Draxonis.
Method for making: above ten simply, and Cinnabaris, Moschus, Mentholum grind impalpable powder, Olibanum, Sanguis Draxonis coarse pulverization, and Flos Carthami, Rhizoma Curcumae Longae, Radix Ilicis Pubescentis are extracted volatile oil, and the aqueous solution after distillation device is in addition collected, and medicinal residues and Semen Strychni, Herba Aristolochiae decoct with water secondary, each 1h.The Bufo siccus coarse pulverization, other fries in shallow oil, and decocts secondary, each 2h.Aqueous solution after merging all decocting liquids and distilling is when heating is concentrated into 2/3 volume, with the Olibanum of coarse pulverization, Sanguis Draxonis adds, and continues to be concentrated into 1/3 volume, filtered while hot, be chilled to room temperature, add 95% ethanol then in filtrate, the limit edged stirs, in solution, contain amount of alcohol and reach about 65%, left standstill 24 hours, get cleaner liquid, precipitation adds 65% ethanol, extracts once again, merges, cleaner liquid reclaims ethanol.Be the thick paste shape 60~70 ℃ of evaporation and concentration to filtrates,, add mixing, promptly volatile oil such as Cinnabaris, Moschus, Mentholum fine powder and Flos Carthami, Rhizoma Curcumae Longaes.
Town's cancer pain rubber plaster preparation
1. raw material pre-treatment: get raw rubber and clean, 50~60 ℃ of heat dryings or dry are cut into bulk with bale splitter, and Colophonium is removed impurity, pulverizes.
2. system rubber plaster
With niggerhead in machinery repeatedly roll compacting reticulate thin slice, be spread out in put on the wire gauze cold, make and eliminate static 18~24h, airtight being dipped in an amount of gasoline treats to stir evenly in the dislocation adhesive supplier after the swelling, gradation adds vaseline, lanoline, liquid paraffin, zinc oxide and Colophonium etc., and add an amount of above-mentioned Chinese medicine condensed cream, and stirring 9h, the cream that makes slurry moves into the creme filter, utilize the spiral loader that heavy-gravity creme was pressed 80 order copper wire screen clothes, elimination impurity.Creme is put on " plaster coating machine " and is coated with cream, cutting, and lid serves as a contrast, and is cut into the fritter of 8cm*8cm, in the plastic bag of packing into, promptly.
Hydroxyl, demethyl speckle insect destructive of the roots of seedlings amine sheet
1. the preparation of Cantharidin
(1) technology path
(acidify, extraction)
(2) technical process 1, cantharidin preparation: by the cantharis coarse powder: concentrated hydrochloric acid: the charge ratio of acetone=1: 0.025: 5.5 feeds intake.Get dry coarse powder and add 0.025 times of concentrated hydrochloric acid, use the acetone extraction 48 hours of 3 times of amounts of coarse powder then, leaching acetone, 2.5 times of acetone extraction of residual pool reuse 48 hours filter, merge acetone extract, residual pool is washed 1 time with proper amount of acetone, merges, and concentrates to reclaim acetone, get dark concentrated grease, promptly have mass crystallization to separate out.Filter, the crystallization petroleum ether is removed pigment and Animal fat, and the washing with alcohol of reuse 95% gets the cantharidin crude product, fusing point 213 for several times---216 ℃, promptly get cantharidin with the acetone recrystallize.
(2) technical process hydroxyl, the preparation of demethyl cantharidimide
1. cantharidin adds rare HNO
3Oxidant is heated to 150-160 ℃, is forced into the 10-15 atmospheric pressure and carries out oxidation reaction, makes the methyl (CH on the side chain
3) be oxidized to carboxyl (CooH).
2. add soda lime NaoH-CaO, heat is carried out decarboxylic reaction altogether, sloughs the carboxyl (CooH) on the side chain, promptly gets cantharidin.
3. feed ammonia (NH
3), pressurization, heating (200 ℃) utilizes the Gabriel synthetic method, synthetic pure primary amine (NH), product has water (H
2O) generate.
4. feed chlorine (Cl
2), irradiation carries out chlorination reaction, and with the H on the Cl atom replacement primary amine groups (NH), product has Hcl to generate.
5. add the NaoH aqueous solution, be hydrolyzed, promptly get hydroxyl demethyl cantharidimide.
3, hydroxyl, the preparation of removing basic cantharidimide tablet
By 100,000 calculating of preparation, need with hydroxyl, demethyl cantharidimide 25g-30g, starch 2kg, Pseudobulbus Bletillae (Rhizoma Bletillae) powder 5kg, magnesium trisilicate 1kg, aluminium hydroxide 2kg, 35% ethanol 9-10kg, magnesium stearate 0.1kg.
Get hydroxyl, demethyl speckle insect destructive of the roots of seedlings amine and starch and place ball mill, ground 24 hours, cross 100 mesh sieves, add Pseudobulbus Bletillae (Rhizoma Bletillae) powder, aluminium hydroxide and magnesium trisilicate, mix, by 40 mesh sieves, mix homogeneously, add 35% ethanol and stir the moistening soft material of making, cross 14 mesh sieves and granulate drying.Again dried granule is added magnesium stearate, after mixing a little, cross 14 order ferrum sieve granulate, abundant again mix homogeneously is stored in the metal bucket that is lined with cloth bag, the chemical examination of weighing, qualified back tabletting.Every hydroxyl, demethyl speckle insect destructive of the roots of seedlings amine 0.25g~0.3g, the heavy 0.101g of sheet.
The helexin sheet
1. the preparation of oleanolic acid
With little SHELIAN, the fruit of the Fructus Ligustri Lucidi of Oleaceae extracted 24 hours with 95% ethanol room temperature, tell filtrate, again with 95% fresh alcohol reflux 2 times (each 6 hours), merge extractive liquid,, concentrating under reduced pressure gets solid residue, be dissolved in the ethanol, transfer PH to 1, separate out crystallization, washing promptly gets the higher oleanolic acid of purity.
2. the preparation of anethole
The coarse pulverization gamin seed is packed in the enamel reactor, add 95% ethanol of Fructus Foeniculi powder weight 1~2 times (weight/volume), added extraction heat 2~3 hours, 75~80 ℃ of heating-up temperatures.Extraction finishes, and filters out filtrate, and filtering residue is pressed extraction procedures extraction 2~3 times again.Merging filtrate, and filtrate is drawn in the alembic, adding thermal distillation, vapo(u)rizing temperature is controlled between 80~85 ℃, reclaims ethanol, under this temperature conditions, till no longer including distillation.Residual fraction after the distillation is the mixture of Oleum Anisi Stellati and water.Through oil-water separation, discard water, promptly get and concentrate Oleum Anisi Stellati.
Get concentrated Oleum Anisi Stellati and add 95% ethanol of 3 times of amounts and 20% medicinal carbon, heating in water bath refluxed 30 minutes, filtered while hot, filtrate cooling, move to stirred crystallization in the ice bath again, drain,, drain again with the small amount of ethanol washing, place 50~60 ℃, drying promptly gets anethole.
3. the preparation of helexin
The dry Caulis Hederae Sinensis stem and leaf and the fruit of coarse pulverization are used methanol room temperature lixiviate 3 days, reclaim methanol, residue is dissolved in weak ammonia, chloroform extraction, and the residue behind the recovery chloroform is dissolved in 90% methanol, with the oil defat, reclaims methanol, promptly gets helexin.
4. ginsenoside's preparation
Extracting method is identical with the preparation method of helexin.Raw material adopts the raw hide Radix Ginseng.
Preparation: by 10,000 calculating of preparation, need with helexin 25g, oleanolic acid 500g, ginsenoside 1000g, anethole 3000g, starch 0.5kg, tapioca starch 2kg, stearic acid sodium sulfonate 0.35kg, magnesium carbonate 0.6kg, magnesium stearate 0.1kg, every contains helexin 2.5mg, and heavy every of theoretical sheet is 0.8g.
Get anethole and magnesium carbonate places ball mill, grind, make the abundant oil suction of magnesium carbonate.Other gets helexin, ginsenoside, oleanolic acid, starch and packs in the ball mill, grinds 24 hours.Two parts of grounds travel are mixed, and cross 100 mesh sieves, add tapioca starch, and the stearic acid sodium sulfonate mixes, and by 40 mesh sieves, mix homogeneously adds 35% ethanol and stirs the moistening soft material of making, and crosses 14 mesh sieves and granulates drying.Again dried granule is added magnesium stearate, after mixing a little, cross 14 order ferrum sieve granulate, abundant again mix homogeneously.Through weighing, chemical examination, qualified after, tabletting.
The photosensitizer part
One, the preparation of magnetic blood quinoline methyl ether (HMME) intravenous fluid
1.3, the preparation of 8--two (1-bromoethyl) deuteroporphyrin IX (DBD)
Removing the fibrosis Sanguis sus domestica by fresh anticoagulant is basic material through the chlorhematin that the digestion of the saturated acetic acid of Nacl makes, under the room temperature in acetic acid with dry HBr low pressure addition de-iron after, promptly make 3,8--two (1-bromoethyl) deuteroporphyrin IX (DBD).
2. the preparation of blood quinoline methyl ether (HMME)
200ml 3,8--two (1-bromoethyl) deuteroporphyrin IX two hydrobromate glacial acetic acid saturated solutions stir following to the mixed liquid of 360mml methanol and 1440ml water, stirring reaction 2~3h, reactant liquor adds acetic acid then and regulates PH to 4~5 with 10mol/L NaoH hydrolysis, the precipitate that the filter collection is separated out, wash 3 times, blot, drying under reduced pressure gets the aubergine solid, and the latter carries out silica gel column chromatography with chloroform cHcl
3--methanol cH
3OH--formic acid HcooH (10: 1: 0.1) eluting,--(1-methoxy ethyl)--8 (or 3)--(1-ethoxy) deuteroporphyrin IX is hematoporphyrin monomethyl ether (HMME) 590mg to get 3 (or 8).
3. prepare the lysate of blood quinoline methyl ether (HMME)
Be adjusted to PH=7 with in 0.5ml, 0.1N, NaoH, stirring 1h solution under the 10mgHMME room temperature with hydrochloric acid, stir evenly, promptly get the lysate of blood quinoline methyl ether (HMME).
4. the preparation of magnetic HMME microcapsule
In 15 parts of benzole solns that contains 10% polystyrene, add 3 parts of magnetic colloid solution (such as iron dextran colloid solution).
To make mean particle dia after the mulser emulsifying is the emulsion first time below the 0.5um; under constantly stirring; emulsion for the first time joined 70 parts the gelatin that contains; polyvinyl alcohol and surfactant are (as nonionic surfactant; Tween 80 and sorbester p17 share); make it in the aqueous solution of protecting colloid material to disperse; produce emulsion for the second time; while stirring temperature is brought up to 35~40 ℃; be incubated a few hours, decompression, drying; remove the semipermeable membrane that solvent forms polymer, promptly make the aqueous solution that contains semi-finished product magnetic microcapsule.
A small amount of blood quinoline methyl ether (HMME) lysate (this amount is determined accurate dosage by later test data) joined 30 parts the gelatin that contains; polyvinyl alcohol and surfactant; Tween 80 and sorbester p17 share; in the aqueous solution of protecting colloid material; abundant mixing; then above-mentioned half-finished magnetic microcapsule aqueous solution is added; while stirring temperature is brought up to 35~40 ℃; be incubated a few hours; drying under reduced pressure; remove semi-transparent film and impurity that solvent forms polymer, promptly make the aqueous solution that contains the HMME microcapsule that is magnetic.Require particle diameter below 1um, also there is a small amount of pore structure on magnetic HMME microcapsule surface, still possesses the physical absorption function, and above-mentioned preparation water uses water for injection.
5. the preparation of magnetic blood quinoline methyl ether (HMME) intravenous fluid
Under the lucifuge condition, with aseptic, under purified blood quinoline methyl ether (HMME) the 10mg room temperature in 0.5ml, 0.1N, stir 1h among the NaoH, solution is adjusted to PH7 with hydrochloric acid, and add an amount of water for injection, to contain the 0.1mg that has an appointment (this amount is determined accurate dosage by later test data) sterilization then, pure magnetic HMME microcapsule aqueous solution adds, be incubated 37 ℃, fully stir, and add an amount of fabaceous lecithin emulsifying agent, transfer PH to 7.4 with 10% natrium carbonicum calcinatum then, and add Nacl and regulate in right amount etc. and to ooze, add adding to the full amount of water for injection, fine straining, embedding is pressure sterilizing in the lucifuge ampoule, promptly gets used for intravenous injection magnetic HMME Emulsion.
Two, the preparation of monoclonal antibody blood quinoline methyl ether (HMME) intravenous fluid
1, blood quinoline methyl ether (HMME) and human serum albumin's (HSA) fusion
(1) human serum albumin's (HSA) dissolving
Lyophilizing human serum albumin (HSA) joined in an amount of 0.9% the sodium chloride normal saline, stir evenly, promptly get human serum albumin's lysate.
(2) dissolving of blood quinoline methyl ether (HMME) will be stirred 1h under the 10mg HMME room temperature in 0.5ml, 0.1N, NaOH, and solution is adjusted to PH=7 with hydrochloric acid, stirs evenly, and promptly gets the lysate of blood quinoline methyl ether (HMME).
(3) fusion of HMME and HSA
A little human serum albumin (HSA) lysate (determining accurate dosage by later test data) is joined in blood quinoline methyl ether (HMME) lysate, be incubated 37 ℃, stir, leave standstill, filter, promptly get the natural fusion liquid of HMME and HSA.
2, conjugate monoclonal antibody-HMME-HSA's is synthetic
Hydroxyl on the terminal leucine of the epsilon-amino of lysine side-chain in the monoclonal antibody molecule and succinyl tetrapeptide is generated amido link to link to each other, again with the other end and the HMME-HSA coupling of succinyl tetrapeptide arm, form conjugate, coupling reaction occurs in the free amine group of lysine on the HMME-HSA complex albumin and the carboxyl of succinic acid forms amido link (See Figure)
3, the preparation of monoclonal antibody HMME--HSA intravenous fluid
With aseptic purified monoclonal antibody HMME-HSA conjugate solution, transfer PH to 7.4 with 10% natrium carbonicum calcinatum, and add Nacl and regulate in right amount etc. and to ooze, add and add to the full amount of water for injection, use sintered glass filter aseptic filtration, under aseptic technique, embedding in the lucifuge ampoule promptly.
Three, the preparation of ferritin blood quinoline methyl ether (HMME) intravenous fluid
1. the preparation of hemoglobin
1. extract erythrocyte and collect healthy people's blood or Placenta Hominis, puerperal 10 liters of blood or directly utilize the preparation serum gamma globulin of human placenta--the dipping extraction process, the erythrocyte of reject under agitation adds its volume 10% concentration and is 2.5% sodium citrate solution anticoagulant, stir, leave standstill, make the erythrocyte natural subsidence, remove the most of blood plasma in upper strata, centrifugal again all the other blood plasma that eliminate of subnatant, the sodium chloride that adds 3 times of amounts 0.9% again, washed twice, the centrifugal overstocked erythrocyte (about 4 liters) of collecting.
2. cell breakage
The erythrocyte that extracts is refrigerated to subzero 15 ℃~20 ℃, makes it to solidify, dissolving lentamente then, so repeatable operation is all broken until erythrocyte.
3. extract hemoglobin
0.4 kilogram of refining sodium chloride (Nacl) joined fully dissolve in 10 liters the distilled water and join then in the broken red blood cell liquid that has returned to room temperature (20 ℃), stir, leave standstill, filter, collect the hemoglobin precipitation of separating out, add sodium chloride in the filtrate again, repetitive operation is repeatedly all separated out until hemoglobin.
4. hemoglobin is refining
With the hemoglobin dialysis desalting of collecting, the desalination hemoglobin adds appropriate amount of deionized water (pure water), stir evenly, and add equivalent acetone, (0-4 ℃) left standstill 4~6 hours under the low temperature, centrifugal collecting precipitation, repetitive operation once after precipitation is used the pure water washes clean, is dewatered twice with dehydrated alcohol, vacuum drying promptly gets the pure product of hemoglobin.
5. the dissolving of hemoglobin
The pure product of hemoglobin are joined in an amount of 0.9% the sodium chloride normal saline, stir evenly, promptly get hemoglobin solutions.
2. hemoglobin and blood quinoline methyl ether (HMME) merge under physiological condition
Under the lucifuge condition, a little hemoglobin lysate (determining accurate dosage by later test data) is joined in the blood quinoline methyl ether solution (aforementioned), be incubated 37 ℃, stir 1h, leave standstill, filter, promptly get the fusion liquid of hemoglobin (ferritin) and blood quinoline methyl ether.
3. the preparation of ferritin blood quinoline methyl ether (HMME) intravenous fluid
Under the lucifuge condition, aseptic, purified above-mentioned ferritin and HMME are merged liquid, add an amount of water for injection, transfer PH to 7.4 with 10% natrium carbonicum calcinatum then, and add Nacl and regulate in right amount etc. and to ooze, add adding to the full amount of water for injection, use sintered glass filter, under the aseptic filtration operating condition, embedding is in the lucifuge ampoule, promptly.
Biochemical medicine part
Cancer cachexia is alleviated the preparation of quiet dropping liquid
1. tryptic preparation
With the Pancreas caprae seu ovis is the extraction method of raw material
(1) technology path
(extraction) (segmentation is saltoutd)
H
2SO
4(NH
4)
2SO
4→ precipitate spends the night Pancreas caprae seu ovis--→ extracting solution----
(2) technical process
1. extract: the fresh or bright Pancreas caprae seu ovis that freezes, peel off fat and connective tissue, rub, every 10kg pancreas slurry adds 0.1mol/L sulfuric acid solution (the 116ml commercial sulphuric acid adds water to 20kg) 20kg, stirs after 1~2 hour, and placement is spent the night.Adding 3.52kg industrial sulphuric acid ammonium gradually next day under constantly stirring, concentration reaches 0.3 saturation, adds in about 1 hour, and all dissolving was placed 3~5 hours again, filter extracting solution.In case of necessity, filtering residue can be used 10L, and the 0.1mol/L sulfuric acid solution extracts 1 time again.
2. segmentation is saltoutd: every 10L extracting solution adds industrial sulphuric acid ammonium 2.73kg under constantly stirring, and adds in 1~2 hour, reaches 0.7 saturation, and placement is spent the night.Inhale next day and go the supernatant (can supply to extract ribonuclease), filter, get the 430g filter cake.Filter cake calculates the ammonium sulfate (CP) that adds 176g/L by lysate and reaches 0.7 saturation with 4 times of amount volume dissolved in distilled water, and placement is spent the night.Next day, decompressing and extracting is collected filter cake.Every 10kg pancreas gets the 300g filter cake approximately.
3. dialysis, crystallization: get the 300g filter cake and add 0.4mol/L, the borate buffer of PH9 (49.4g boric acid is dissolved in the distilled water, adds 80ml, 5mol/L sodium hydroxide or 16g solid sodium hydroxide, with distilled water diluting to 1L, PH9~10.When mixing with saturated magnesium sulfate, pH value can reduce, and therefore, PH needn't be transferred to 9.1 times of adding distil water dilution, be the 0.4mol/L borate buffer) 200ml dissolving, remove by filter insoluble matter, add 200ml " crystallization dialysis solution " (get the 0.4mol/L borate buffer and saturated magnesium sulfate equal-volume mixes, PH is lower than at 8 o'clock, drips gradually with saturated potassium carbonate and transfers to PH8) again, pack in the bag filter, in the time of 0~5 ℃, " crystallization dialysis solution " dialysed, changed once in per 24 hours " crystallization dialysis solution ", begin to occur crystallization after 3~4 days in the bag filter, about one all crystallizations are complete.
4. recrystallize, drying: the bag taking intercrystalline filters with buchner funnel, approximately the crystallization of 22g trypsin, the same operation recrystallize 1 time approximately 18g.Crystallization is dissolved among 0.01mol/L hydrochloric acid (the 8ml hydrochloric acid adding distil water 10L) 100ml, dialyses in 0.01mol/L hydrochloric acid and desalts, and lyophilization gets injection crystallization Pancreas caprae seu ovis protease.Yield is 0.6g/kg, enzyme activity 150 units/and more than the milligram.
2. the preparation of lysozyme
(1) technology path (absorption) (foreigh protein removing) 724 resin water, phosphate buffer--------→-→-------------→ 0~5 ℃ of PH6.5 of adsorbate Ovum Gallus domesticus album (eluting) (precipitation) (dialysis), 10% (NH
4)
2SO
440% (NH
4)
2SO
4Distilled water------------------→ eluent----------------→ crude product--------------→
Divide 4 dissolvings
(saltouing) (drying)
NaoH, Hcl, Nacl acetone dialysis solution--------------→ wet lysozyme----------→ first PH8.5~9, back PH3., 50 ℃ (chromatography)
The DEAE--C lysozyme-------→ injection lysozyme purification
(2) technical process
1. raw material is handled: fresh or freezing Ovum Gallus domesticus album 70kg, and to survey PH with reagent paper and should be about 8, the copper that thawed sieve is removed the umbilical cord in the Ovum Gallus domesticus album, eggshell fragments and other impurity.
2. absorption: temperature drops to about 5 ℃, adds the 724 resin 10kg (weight in wet base) that handle well in stirring resin all is suspended in the Ovum Gallus domesticus album, remains on 0~5 ℃, and stirring and adsorbing 5 hours moves into Ovum Gallus domesticus album 0~5 ℃ in freezer again, and is static, spends the night.
3. foreigh protein removing, eluting, precipitation: the supernatant is inclined to gradually, and the protein that lower-layer resin is adhered to the clear water flush away is washed 4 times repeatedly, notices preventing that resin runs off the part of at last the resin sucking filtration being anhydrated.Other gets PH6.5,0, and 15mol/L phosphate buffer 24L divides to add for 3 times in the resin, stir about 15 minutes, each back decompress filter branch that anhydrates that stirs.Reuse 10% ammonium sulfate 18L divides 4 times the eluting lysozyme, stirs half an hour at every turn, and filtration is drained.The merging eluent adds 32% (W/V) solid ammonium sulfate by cumulative volume and makes content reach 40% concentration, and the adularescent precipitation produces, and place and spends the night at cold place, the siphon supernatant, and precipitation and centrifugal separation or sucking filtration get crude product.
4. dialysis: crude product adding distil water 1.5kg is made it dissolving, and the bag filter of packing in the freezer, was dialysed 24~36 hours, removed most of ammonium sulfate, got dialysis solution.
5. saltout: will clarify dialysis solution, slowly drip the 1mol/L sodium hydroxide, constantly stir simultaneously, pH value rises at 8.5~9 o'clock, if any white precipitate, should centrifugally immediately remove, in stirring, add 3mol/L hydrochloric acid then, make solution PH reach 3.5, by volume slowly add 5% solid sodium chloride, be that adularescent precipitation is separated out, placed 48 hours at 0~5 ℃ of freezer, centrifugal or filter the lysozyme precipitation.
6. dry: precipitation adds 10 times of amounts and is chilled to 0 ℃ anhydrous propanone, constantly stirs, and makes the granule pine thin, and a few hours are left standstill at cold place, and with funnel elimination acetone, precipitation is used vacuum drying, till no acetone stink, promptly gets oral or external lysozyme raw material.
As without the acetone dehydration, can dialyse, its dialysis solution lyophilization gets the not lysozyme goods of sodium chloride-containing.Yield is calculated as 2.5% by Ovum Gallus domesticus album weight.
7. DEAE--C chromatography, purification: the crystallization lysozyme of sodium chloride-containing is not dissolved in the PH4.6 aqueous acetic acid, transfer the centrifugal precipitation of removing of PH8.5, clear liquid passes through 0.01mol/L, the DEAE-C post that PH8.5 phosphate buffer balance is crossed, suitably the control flow velocity is collected effluent, transfers PH5.5, lyophilizing, the response rate nearly 100%.Promptly get highly purified injection lysozyme.3. the preparation of papain (1) technology path
(squeezing) (absorption)
Sodium benzoate kaolin Fructus Chaenomelis------→ press juice-------→ adsorbate
10℃
(eluting) (saltouing sucking filtration) Na
2CO
3Or NaoH, (NH
4)
2SO
4Hcl, (NH
4)
2SO
4----------------------------------→ eluent------------------------------→
PH6.5~7 PH4.5~5
(dissolving) (stablizing)
Tap water, NaoH EDTA-2Na, SO
2, the Vc semifinished product--------------→ clear liquor-------------------------→
PH7~7.5
(absorption) (eluting)
Tannic acid Vc stabilizing solution--→ tannic acid adsorbate----→ eluent---
PH4.5 (drying is pulverized)-----→ finished product
(2) technical process
1. squeezing: Fructus Chaenomelis is extruded juice through squeezer, add 0.05% sodium benzoate by fruit juice and make antiseptic, the raw material storage low-temp storage of making a gift to someone is standby.
2. absorption, eluting: press fruit for cider and put in the stainless steel cold wall tank, constantly stir, rotating speed 40~60r/min adds 4% kaolin of juice amount, in 10 ℃ of absorption 15~20 minutes, standing over night.Inferior kaolin sedimentation in morning is good, and supernatant is removed in siphon, stays wet potter's clay, add sodium carbonate saturated solution or 6.6% hydrochlorinate sodium and regulate PH6.5~7, add ammonium sulfate or edible refined salt again, stirred 25~30 minutes by wet soil 50%, carry out eluting, promptly carry out filter pressing with pressure filter.
3. saltout sucking filtration: pressing filtering liquid adds 9% hydrochloric acid (concentrated hydrochloric acid: water=1: 3) regulate PH4.5~5, add 20~25% ammonium sulfate (or 25% refined salt) again and saltout, stir gently with wooden stick, make the sodium sulfate dissolving, the seasoning freezer in steel drum.In inferior morning, siphon goes out the upper strata metabisulfite solution, and lower floor separates out rare enzyme and sticks with paste, and centrifugalize gets thick enzyme and sticks with paste.Remove the seasoning of part of sulfuric acid ammonium liquid in-20 ℃ through the buchner funnel sucking filtration, wait to make with extra care.
4. dissolving: get the tap water that the enzyme crude product adds 8~10 times of amounts, regulate PH7~7.5, be stirred to dissolving gently with 16% sodium hydroxide.Prevent foaming, filter pressing rapidly separates and removes impurity, gets clear liquor.Use a small amount of tap water flushing pipe and pressure filter at last, washing liquid and above-mentioned clear liquor merge.
5. stable, absorption: above-mentioned clear liquor, add 0.05% EDTA-2Na by the juice amount, 0.06% sulfur dioxide, 0.02% ascorbic acid used as stabilizers adds 0.4~0.6% tannic acid according to quantity and adsorbs after the stirring, must precipitate adsorbate.
6. eluting, drying: get the tannic acid adsorbate, with PH4.5 ascorbic acid solution eluting, filtration press dry, drying under reduced pressure, injection papain purification elaboration.
4. the preparation of trypsin papain lysozyme complex
Get 2% lysozyme soln 1000ml and act on mutually with 2% Trypsin solution 500ml and 2% papain solution 500ml, at PH4.5,4 ℃ kept 24 hours, and promptly separated out lysozyme papain trypsin complex.
With the lysozyme papain trypsin complex lyophilization of separating out, and add an amount of DL--threonine used as stabilizers, behind the mixing, in the vial of band plug and the aluminium lid of packing into, put in the refrigerator and preserve, can take out when preparing quiet dropping liquid.
5. the preparation of quiet dropping liquid
(1) with an amount of NaHco
3Pure product add the injection water and are mixed with 200ml, and the solution of PH7.4 is filtered to clarification with No. 4 sintered glass funnels, (preferably fills nitrogen) at 0.5kg/cm in the infusion bottle of the 250ml that packs into then
2Sterilized 30 minutes, and a collection ofly went out 100 bottles.
(2) with an amount of Na
2Co
3With the pure product of NaoH, press Naco
3: NaoH=3: 1, add the injection water and be mixed with 2 50ml, the solution of PH12 is filtered to clarification with No. 4 sintered glass funnels, (preferably fills nitrogen) at 0.5kg/cm in the infusion bottle of the 250ml that packs into then
2Sterilized 30 minutes.A collection ofly go out 1 bottle.
6. the preparation of quiet dropping liquid
Using " cancer cachexia is alleviated quiet dropping liquid " before, at first measuring the pH value of blood samples of patients, using " disposable syringe " to extract the NaHco of PH7.4 then with accurate PH meter (a kind of instrument of measuring the solution pH value)
3Transfusion 5ml injects the lyophilized formulations bottle that lysozyme papain trypsin complex is housed, and jolting is fully dissolved complex, changes a syringe then, takes out most complex lysate, injects the NaHco of PH7.4
3In the infusion bottle.According to the blood samples of patients pH value, extract (the Naco of PH12 with syringe
3+ NaoH) transfusion, the NaHco of injection PH7.4
3In the infusion bottle, transfer PH7.5~8.5, just can give patient's intravenous drip then with the PH meter.Cancer patient's blood pH is adjusted to about healthy people's PH7.4 as far as possible, and this infuses with joining with usefulness, must not shelve more than 1 hour at room temperature, in case the trypsin inactivation.This transfusion is preferably in and puts, chemotherapy intravenous drip in preceding 12 hours, once a day.But make sure to keep in mind to use " cancer cachexia is alleviated quiet dropping liquid " in the hemorrhage phase of cancer.
The quiet dropping liquid of polyinosini--Thymosin--Radix Isatidis
The preparation of Thymosin
1. process route
(smash to pieces, extract)
Rub normal saline porcine thymus--→ thymus fragment------→ extracting solution (component 1)
(precipitation) (heating foreigh protein removing) acetone------→ supernatant (component 2)--80 ℃ of → acetone powders (component 3), 10 ℃ of 15min
(2) technical process
(1) fresh or freezing porcine thymus is removed fat and rub after, add 3 times of amount normal saline, in tissue mashing machine, make homogenate, after 14000*g is centrifugal extracting solution (component 1).
(2) heating foreigh protein removing: 80 ℃ of heating of extracting solution 15min, to the thermally labile part, the centrifugal precipitation of removing gets supernatant (component 2) with precipitation.
(3) precipitation: supernatant is cooled to 4 ℃, adds-10 ℃ of acetone of 5 times of volumes, filters collecting precipitation, gets acetone powder (component 3) after the drying.
(4) segmentation is saltoutd: acetone powder is dissolved in the PH7.0 phosphate buffered solution, and adding ammonium sulfate to saturation is 0.25, and it is 4.0 that centrifugal removal precipitation is transferred PH to thermally labile part supernatant (component 4), and adding ammonium sulfate to saturation is 0.50, the thing of must saltouing.
(5) ultrafiltration: the thing of will saltouing is dissolved in the 10mmol/L Tris-Hcl buffer of PH8.0, and ultrafiltration is got molecular weight at the ultrafiltrate below 15000.
(6) desalination, drying: ultrafiltrate is after Sephadex G-25 desalination, and lyophilization gets thymosin (component 5).
The preparation of polyinosinic acid (polyinosini Poly I:C)
Production technology
1, substrate 5 '-preparation of nucleoside diphosphate pyridiniujm
5 '-nucleoside=phosphoric acid pyridiniujm (being the CDP pyridiniujm, the IDP pyridiniujm)
2, the preparation of immobilization polynucleotide phosphorylase.
(1) preparation of enzyme:
Collect enzyme the highest part alive in the 0.35mol/LNacl eluent.
(2) preparation of solid phase carrier:
----------------→------ethyl sulfone aniline etherificate NaNo2+Hcl diazotising----------→--→--------------------------→ solid phase carrier
(3) immobilization polynucleotide phosphorylase is gone into carrier in the ice bath with the enzyme drop of separation and purification.Obtain covalently bound immobilization polynucleotide phosphorylase.
3.PoIy I:C preparation
(1) substrate pretreatment: the CDP pyridiniujm changes into lithium salts, and IDP changes into sodium salt.
(2) enzymatic reaction: (every milliliter of reactant liquor contains u mol/L number) IDP or CDP15; Tris 150; Mgcl2 6; EDTA1; Polymerase 5 units, PH9.0,37 ℃, 3-4 hour).Transfer PH1.5~2.0 with hydrochloric acid, make PoIyI (or PoIyC) precipitation, centrifugal immediately, after this in phosphate buffer, dissolve, mix with PoIyC Deng mole PoIyI, filter, filtrate is transferred PH1.5~2.0 with hydrochloric acid, is stirred to crystallization and separates out fully, be placed on crystallization below 10 ℃ 1 hour, refilter and collect crystallization absolute ethanol washing 3 times, drain 60 ℃ of vacuum dryings, promptly get PoIy I:C finished product.
The preparation of Radix Isatidis powder injection
With the Radix Isatidis coarse pulverization, get 1.5kg, heating decocts three times, and each 30 minutes, filter, merging filtrate is concentrated into 1500ml, adds doubling dose 95% ethanol, filters, and reclaims ethanol.To remain medicinal liquid and be concentrated into 700~1000ml in water-bath, the cooling back adds ether 250ml, discards ether after leaving standstill, and adds 2% gelatin solution of 2 times of amounts of medicinal liquid again, sucking filtration.Filtrate adds 2 times of amount 95% ethanol again, leaves standstill 24 hours, filters, and reclaims ethanol, is chilled to room temperature, filters, and the filtrate spray drying is made instant injectable powder.
The preparation of the quiet dropping liquid of polyinosini--Thymosin--Radix Isatidis
With Thymosin, the polyinosinic acid crystal powder mixes by 1: 1: 0.5 with the instant injectable powder of Radix Isatidis.And add an amount of mannitol used as stabilizers, after the mixing, in the vial of pack into band plug and aluminium lid.Before facing usefulness, use 250ml, the transfusion of 0.9% sodium chloride is made into quiet dropping liquid, with joining with usefulness.
Merging chemicotherapy dwindles the tumor body and carries out the used X-ray magnetic therapy machine of optical dynamic therapy and drug system treatment thereof the concrete using method greater than the above tumor body of 3cm*3cm.
After using following medicine 1h, 43 ℃ of the constant temperature of the most handy X-ray magnetic therapy machine pulsation Magnetotherapeutic apparatus (only opening the solenoid power supply, magnetic pole malleation cancer place) constant temperature, pulsation magnetic therapy 30min.(magnetic field intensity 4000GS~6000GS).
For the tumor body greater than the cancer patient more than the 3cm*3cm, 24h before chemicotherapy, first intravenous drip " cancer cachexia is alleviated quiet dropping liquid " is at interval taken the anti-compound recipe complex capsule in osmanthus behind the 6h.Under the situation of not using the X-ray magnetic therapy machine, carry out radiotherapy behind the 5h or take chemotherapeutics, 6h clothes XIAOLIU PIAN behind the chemicotherapy, clothes three plerosis side's complex capsules behind the 5h are obeyed hydroxyl again behind the 6h at interval, demethyl speckle insect destructive of the roots of seedlings amine sheet or clothes helexin sheet.24h after chemicotherapy, the quiet dropping liquid of intravenous drip polyinosini-Thymosin is further strengthened the therapeutic effect of aforementioned medicine.
Attention: at the chemicotherapy resting stage, not take the anti-compound recipe complex capsule in osmanthus for well, in addition, and in the carcino-matous hemorrhage phase, must not be with " cancer cachexia is alleviated quiet dropping liquid.The constant temperature pulsation Magnetotherapeutic apparatus of use X-ray magnetic smelting cancer machine carries out electric heating magnetic and rules by law thoroughly when treating, and asks one behind clothes cancer therapy drug 1h, carries out, and please not want separately or use in advance, makes sure to keep in mind.
To the patient of skin carcinoma, esophageal carcinoma, preferably using the bundle group medicine of osmanthus anti-food (skin) compound capsule simultaneously--skin carcinoma ointment for promoting muscle growth and esophageal carcinoma block alleviates containing sugar-tablet.When cancer pain was violent, pain spot sticked " town cancer pain rubber plaster ", and with the constant temperature pulsation Magnetotherapeutic apparatus of X-ray magnetic therapy machine, the positive pressure pain point of magnetic pole, the magnetic therapy of pulsing 1h can be alleviated B section cancer pain rapidly.
When utilizing the treatment of said medicine, apparatus to make the tumor body narrow down to less than 3cm*3cm, intravenous injection ferritin HMME or magnetic HMME Intravenous injection solution are behind the 1h, the constant temperature Magnetotherapeutic apparatus of X-ray magnetic therapy machine is opened, magnetic pole malleation cancer place, heated at constant temperature 1h, magnetic control location 2h.After stopping 2h, the silicon fiber of X-ray magnetic therapy machine is imported in the body cavity apart from tumor surface 3cm part by endoscope.Open the constant temperature Magnetotherapeutic apparatus of X-ray magnetic therapy machine simultaneously, the cancer district of magnetic pole malleation body surface, and open the X line, laser aid and connect the power supply of two metallic plates, the light dosage of control X-ray can carry out the tumor dynamic therapy and (PDT).
If intravenous injection monoclonal antibody HMME Intravenous injection solution when then carrying out photodynamic tumor treatment (PDT), without the constant temperature Magnetotherapeutic apparatus of X-ray magnetic therapy machine, is only used the X line, laser aid and charged particle accelerator.
When clinical treatment, can carry out repeatedly PDT or anti-according to tumor body size and biopsy situation with osmanthus, three plerosis side's complex capsules, XIAOLIU PIAN is carried out prognosis, in case recurrence.
Below in conjunction with accompanying drawing X-ray magnetic therapy machine of the present invention is described:
1. two of charged particle accelerator round-meshed metallic plates must be placed in the glass tube with vacuum.The cathode metal plate is placed on outside the solenoid, and the negative pole metallic plate is placed in the solenoid, apart from solenoid centre position 3~5cm.
2. pass the X ray of plane mirror and converge into a branch of hybrid circuit structure through the laser of flat mirror reflects, this hybrid circuit structure is after the electric field of charged particle accelerator quickens, and the aperture of being deployed in the middle of solenoid by special silicon fiber is derived again.This optical fiber special feature is that the outside of glass stamen line is a raw material with Indium sesquioxide., stannum oxide earlier, adopts the deielectric-coating of " Vacuum Coating method " plating one deck blocking-up electromagnetic wave path, and then wraps up the stamen line with " covering ".
3. the thermometer of thermostat is placed on the outside of spiral piping arrangement, and armature preferably is placed on solenoidal centre position.
Claims (15)
1, the X-ray magnetic therapy machine is that a kind of X line, laser, the three-in-one light power of constant temperature pulsation magnetic therapy are controlled the cancer medical apparatus and instruments.
It is characterized in that forming by the special silicon fiber of X-ray apparatus (1) laser device (2) charged particle accelerator (3) pulsation Magnetotherapeutic apparatus (4) thermostat (5) parts such as (6).
2, the anti-compound recipe complex capsule in osmanthus is a kind of chemicotherapy drug combination, and is the drug distribution modifying agent of photosensitizer in the tumor photodynamic therapy (PDT).
It is characterized in that directly making 40 order granules by basis side (1) Ramulus Cinnamomi, Poria, Cortex Moutan, Semen Persicae, each 9g of Radix Paeoniae, basis side (2) Herba Agrimoniae 10g, Herba Solani Lyrati 30g, Herba Solani Nigri 25g, Semen Arecae 15g, Rhizoma Pinelliae Preparata 10g, Radix Glycyrrhizae 5g system 40 order enteric-coated microcapsule granules, (1) square granule and (2) square enteric-coated microcapsule granule then, mixing, pack in the hard capsule case, be prepared into capsule.
3, according to claim 2, the skin carcinoma ointment for promoting muscle growth is the binding medicine of osmanthus anti-skin compound recipe complex capsule, is a kind of skin carcinoma coating externally-applied ointment.
It is characterized in that making ointment by the substrate of prescription (1) Radix Angelicae Dahuricae, Radix Arnebiae (Radix Lithospermi), Radix Angelicae Sinensis, Rhizoma Arisaematis, Rhizoma Pinelliae, Semen Hyoscyami, Olibanum, Myrrha, Cortex Phellodendri, Radix Scutellariae, Rhizoma Coptidis, Indigo Naturalis, Radix Aconiti, Radix Glycyrrhizae, catechu, Semen phaseoli radiati powder, each equivalent pharmacy oil of Calamina and prescription (2) Cera Chinensis 7.2g, Borneolum Syntheticum 6g, anhydrous lanolin 2.4g, prescription (1) medicine oil 192g, Semen phaseoli radiati powder 57.6g, Cera Flava 7.2g, jasmin essence 0.18g, white vaseline 12g.
4, according to claim 2, it is the binding medicine of anti-relapse due to improper diet side, osmanthus complex capsule that esophageal carcinoma blocks containing of alleviation sugar-tablet, is that a kind of esophageal carcinoma blocks alleviation holding in the mouth for dissolving drug sugar-tablet.
It is characterized in that by prescription: Pseudobulbus Cremastrae Seu Pleiones, each 60g of Galla Chinensis, Knoxia valerianoides 45g, Moschus, each 9g of Realgar, Semen Euphorbiae 30g, Sal Ammoniacus, each 7g of Calculus Bovis, Oleum sesami, syrup are pressed into the holding in the mouth for dissolving drug sugar-tablet in right amount.
5, three plerosis side's complex capsules are a kind of chemicotherapy supports, improving agent.
It is characterized in that directly making 40 order granules by prescription (1) Radix Rehmanniae Preparata 15g, Poria 8g, Radix Paeoniae Alba 8g, Radix Astragali 15g, Radix Ginseng 8g, Radix Angelicae Sinensis 10g, Cortex Cinnamomi 8g, Radix Glycyrrhizae Preparata 5g, Rhizoma Chuanxiong 5g, Rhizoma Atractylodis Macrocephalae preparata 10g; prescription (2) maljoe; Seem Lablab Album phytohemagglutinin (PHA) 50mg, saikoside D and each 40mg of Radix Bupleuri polysaccharide; Grifola umbellata polysaccharide 40mg system 40 order enteric-coated microcapsule granules; prescription (1) granule and prescription (2) enteric-coated microcapsule granule mixing then; pack in the hard capsule, be prepared into capsule.
6, XIAOLIU PIAN is a kind of chemicotherapy drug combination, use simultaneously with chemicotherapy, but the potentiation chemicotherapy, and the effect that prevents eliminating side effect of radiotherapy and chemotherapy to is arranged.
It is characterized in that making condensed cream by prescription (1) Fructus Aurantii 30g, Rhizoma Bolbostematis 20g, Oletum Trogopterori 15g, Herba Agrimoniae 18g, Resina Toxicodendri (stir-fry) 6g, Pseudobulbus Cremastrae Seu Pleiones 20g, Radix Curcumae 18g, Alumen 18g, Sal Nitri 18g, Semen Strychni (processed) 12g, Semen Euphorbiae 15g, prescription (2) magnesium stearate 100g prescription (1) condensed cream 1750g, starch 250g elder brother expect tabletting, use the Indigo Naturalis coating.
7, town's cancer pain rubber plaster is that a kind of pain spot sticks and uses the chemicotherapy support, the auxilliary product for the treatment of.
It is characterized in that by prescription: Bufo siccus (doing all), a Flos Carthami 30g, Rhizoma Curcumae Longae, Cinnabaris, each 15g of Olibanum, Semen Strychni 20g, Moschus 2g, Herba Aristolochiae 30g, Mentholum 30g, Radix Ilicis Pubescentis, each 15g system condensed cream of Sanguis Draxonis add in the rubber cream, then through being coated with cream, cutting, the lid lining, pack is made.
8, hydroxyl, demethyl speckle insect destructive of the roots of seedlings amine sheet is a kind of chemicotherapy drug combination, it can not only kill and wound cancerous cell, and immunosuppressant not, is the better anticancer agent of sending an expedition against.
It is characterized in that by prescription: hydroxyl, demethyl speckle insect destructive of the roots of seedlings amine 25g-30g, starch 2kg, Pseudobulbus Bletillae (Rhizoma Bletillae) powder 5kg, magnesium trisilicate 1kg, aluminium hydroxide 2kg, 35% ethanol 9-10kg, magnesium stearate 0.1kg, batch mixing, tabletting, and get.
9, the helexin sheet is a kind of chemicotherapy drug combination, and it also has mutation-resisting functional when having obvious cytotoxicity, be the comparatively ideal anticancer agent of sending an expedition against.
It is characterized in that by prescription: helexin 25g, oleanolic acid 500g, anethole 3000g, ginsenoside 1000g, starch 0.5kg, tapioca starch 2kg, stearic acid sodium sulfonate 0.35kg, magnesium carbonate 0.6kg, magnesium stearate 0.1kg, batch mixing, tabletting, and get.
10, blood quinoline methyl ether (HMME) lysate is a kind of not as the photosensitizer of the usefulness of quiet notes.
The blood quinoline methyl ether (HMME) that it is characterized in that preparing is made crude drug through chemolysis.
11, according to claim 10, monoclonal antibody blood quinoline methyl ether (HMME) Intravenous injection solution is the targeted drug of deriving of blood quinoline methyl ether (HMME) lysate.
It is characterized in that blood quinoline methyl ether (HMME) merges with human serum albumin (HSA) earlier, synthetic with the monoclonal antibody conjugation again, prepare Intravenous injection solution then.
12, according to claim 10, ferritin blood quinoline methyl ether (HMME) Intravenous injection solution be the magnetic control guide-localization medicine of deriving of blood quinoline methyl ether (HMME) lysate.
It is characterized in that ferritin and blood quinoline methyl ether (HMME) lysate elder generation natural fusion, prepare Intravenous injection solution then.
13, according to claim 10.Magnetic blood quinoline methyl ether (HMME) Intravenous injection solution is the magnetic control guide-localization medicine of deriving of blood quinoline methyl ether (HMME) lysate.
It is characterized in that preparation magnetic HMME microcapsule (particle diameter is below 0.8um) earlier, and then prepare Intravenous injection solution with blood quinoline methyl ether (HMME) lysate.
14, to alleviate quiet dropping liquid be a kind of adjustment cancer blood samples of patients pH value to cancer cachexia, dissolving digestion tumor cancer slough, when eliminating accompanying infection, the pathogenic bacteria of generation and virus, dissolve the blood clot that hemorrhage back produces, eliminate edema, abscess is got rid of hydrops, reduce blood agglutinated degree, be beneficial to these carcinous rubbish, toxin such as cancer slough, the internal milieu improving agent that excretes as early as possible, and cancer cachexia to alleviate quiet dropping liquid still be a kind of chemicotherapy improving agent.
It is characterized in that according to cancer blood samples of patients pH value preparation lysozyme papain trypsin complex NaHCO
3Quiet dropping liquid.
15, the quiet dropping liquid of polyinosini-Thymosin-Radix Isatidis is not only the auxilliary mutually immunomodulator of a kind of attack and defense, but also is that a kind of chemicotherapy is supported synergist.
It is characterized in that the preparation polyinosinic acid-plain F5-Radix Isatidis of breast pancreas mixture earlier, and then the quiet dropping liquid of preparation Nacl.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00117845 CN1316279A (en) | 2000-05-08 | 2000-05-08 | X-ray magnetic therapy machine for PDT therapy of cancer by combining radiatherapy with chemicotherapy and its medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00117845 CN1316279A (en) | 2000-05-08 | 2000-05-08 | X-ray magnetic therapy machine for PDT therapy of cancer by combining radiatherapy with chemicotherapy and its medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1316279A true CN1316279A (en) | 2001-10-10 |
Family
ID=4587083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00117845 Pending CN1316279A (en) | 2000-05-08 | 2000-05-08 | X-ray magnetic therapy machine for PDT therapy of cancer by combining radiatherapy with chemicotherapy and its medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1316279A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101927065A (en) * | 2009-01-16 | 2010-12-29 | 北卡罗来纳大学查珀尔希尔分校 | Compact microbeam radiation therapy system and method for cancer treatment and research |
| US10835199B2 (en) | 2016-02-01 | 2020-11-17 | The University Of North Carolina At Chapel Hill | Optical geometry calibration devices, systems, and related methods for three dimensional x-ray imaging |
| US10980494B2 (en) | 2014-10-20 | 2021-04-20 | The University Of North Carolina At Chapel Hill | Systems and related methods for stationary digital chest tomosynthesis (s-DCT) imaging |
-
2000
- 2000-05-08 CN CN 00117845 patent/CN1316279A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101927065A (en) * | 2009-01-16 | 2010-12-29 | 北卡罗来纳大学查珀尔希尔分校 | Compact microbeam radiation therapy system and method for cancer treatment and research |
| CN101927065B (en) * | 2009-01-16 | 2014-12-17 | 北卡罗来纳大学查珀尔希尔分校 | Compact microbeam radiation therapy systems and methods for cancer treatment and research |
| US10980494B2 (en) | 2014-10-20 | 2021-04-20 | The University Of North Carolina At Chapel Hill | Systems and related methods for stationary digital chest tomosynthesis (s-DCT) imaging |
| US12193852B2 (en) | 2014-10-20 | 2025-01-14 | The University Of North Carolina At Chapel Hill | Systems and related methods for stationary digital chest tomosynthesis (s-DCT) imaging |
| US10835199B2 (en) | 2016-02-01 | 2020-11-17 | The University Of North Carolina At Chapel Hill | Optical geometry calibration devices, systems, and related methods for three dimensional x-ray imaging |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1309399C (en) | Compound 'Shuanghuanglian' preparation and preparing process thereof | |
| CN101972479B (en) | Preparation process of intravenous injection human immunoglobulin | |
| CN104231075B (en) | Preparation process of human hepatitis B immunoglobulin | |
| CN103239706A (en) | Earthworm protein for reducing blood glucose, improving microcirculation and eliminating diabetic complication and application thereof | |
| CN101455750B (en) | Extraction method of coptis detoxifcation decoction active site and use thereof | |
| CN1316279A (en) | X-ray magnetic therapy machine for PDT therapy of cancer by combining radiatherapy with chemicotherapy and its medicine | |
| CN1256124C (en) | Blood-supplementing medicine composition | |
| CN118465250B (en) | A method for optimizing CAR-NK cell injection | |
| CN101161232A (en) | Method of producing intravenous injection human hepatitis b immune globulin | |
| CN1778824A (en) | Several homogeneous tremella polysaccharides and their extraction methods and pharmaceutical compositions containing the compound as an active ingredient | |
| CN1478537A (en) | Chinese medicinal composition for anti-cancer and analgesia, its preparation method and its application in the preparation of product and medicine for treating cancer and analgesia | |
| CN1586500A (en) | Disodium cantharidinate injection for treating tumor and its preparing method | |
| CN1123663A (en) | Composition for curing angicardiopathy and its production and usage | |
| CN1714842A (en) | Chinese medicine composition for smoothing liver-gallbladder and clearing heat and detoxicating and its preparing method | |
| CN1205982C (en) | Xiangdan drop liquid for treating angiocardiopathy | |
| CN116549499B (en) | Application of effective part of pokeberry fermentation broth extract in preparation of antitumor drugs | |
| CN1509729A (en) | Yanning adjuvant | |
| CN120550080A (en) | Preparation method and application of tangerine peel and kudzu root polypeptide composition | |
| CN109464652A (en) | A kind of composition and its preparation method and application for poultry diarrhea | |
| CN109485711B (en) | Ant lion small-molecule peptide and separation and purification method and application thereof | |
| CN1651017A (en) | Pharmaceutical composition and preparation method for treating cervical spondylosis | |
| CN1562272A (en) | Medication for curing secondary anemia, iron deficiency anemia and preparation method | |
| CN100335106C (en) | Traditional Chinese medicine composition for treating intelligence impairment and dementia and preparation method thereof | |
| CN1513508A (en) | Medicine composition for treating uppe respiration channel infetion and its preparing process | |
| CN1091312A (en) | Queen ant extrat oral liquid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |